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Epilepsy is the third main accountable cause for neurological debility around the world and 
is showed via reappearance of unprovoked seizures and resultant distressing consequences in 
patients and their caretakers. Around seventy million individuals all over the globe have epi-
lepsy, and ninety percent of them are placed in developing international locations (Amudhan et 
al., 2015). It is well known that liraglutide is primarily employed in the management of type 2 
diabetes mellitus. The drug acts as a GLP-1 agonist whereby it exerts its principal mechanism 
of action. The drug works by increasing β cell targeted release of insulin. The eventual syner-
gistic effects result in an enhanced glycemic management combined with better lipid digestion 
(Ladenheim, 2015). However, it was recently discovered that, in addition to its antidiabetic 
potential, it also has a potent neuroprotective function. Much of this is achieved by the ability 
of the drug to enhance the retention capability of memory in mice. Moreover, studies done on 
mice have confirmed the effectiveness of liraglutide in improving the total hippocampal py-
ramidal neuronal number (Hansen et al., 2015). The goal of this research was therefore to study 
the anticonvulsant potential of this drug on picrotoxin-induced seizures in mice. The study was 
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conducted in albino mice that weighed between 20 g and 25 g. The animals were housed care-
fully in standard mice cages with the usual mice bedding made of husk. A controlled tempera-
ture of 24 ± 2 °C and a relative humidity range of 30-70 % were maintained when the animals 
were housed in the cages. In addition, a 12 h:12 h light and dark cycle were also maintained. 
The mice were given free access to drinking water and commercial mice pellet. We used four 
sets of mice with six mice in each set (n=6). The first set of mice were administered with 0.9 % 
(w/v) normal saline. These mice served as normal control animals and were administered a dose 
of 1 mL/100 g of normal saline. The second set of mice were administered with standard 
clonazepam of 1 mg/kg. This group of animals was labeled as positive control animals. The 
third and fourth sets of mice were administered with 100 µg/kg and 200 µg/kg of liraglutide 
respectively. All the drugs were administered through intraperitoneal route.  
The anticonvulsant potential of liraglutide was established through Picrotoxin-induced sei-
zures. Thirty minutes after the drugs were administered, the mice were subjected to the induc-
tion of clonic seizures with the help of a single dose of 7.5 mg/kg of picrotoxin. The protective 
effect of the test drugs was measured through observation of the mice for a period of 15 minutes. 
The number of mice that failed to produce a convulsion within the 15 minutes of observation 
time was marked as protected (Taiwe et al., 2016). Time durations of onset and that of clonic 
or tonic seizures were also measured. After all, observations concluded, the mice were sacri-
ficed by decapitation. The brains from all animals were extracted. The cerebral hemispheres 
from the extracted brains were separated into two separate parts; left and right brain hemisphere 
tissues. Reduced glutathione studies were done on one of the parts and GABA studies were 
performed on the other part. Both studies involved preparation of a 10 % w/v homogenate, 
formulated using ice cold 0.1 M phosphate buffer (pH 7.4) and 0.01M hydrochloric acid re-
spectively.  
The measurement for brain reduced glutathione (GSH) levels was performed by initially 
mixing the preformulated brain homogenate with an equal amount of 10 % trichloroacetic acid 
and then removing the unwanted proteins through centrifugation and then collecting the super-
natant mixture which is devoid of any proteins. The supernatant obtained (100 µl) is then mixed 
with 2 mL of 0.3 M phosphate buffer (pH 8.4), 0.5 ml of 0.04 % DTNB in 1 % trisodium citrate 
and 0.4 ml of double distilled water. These were added in succession. To measure the amount 
of GSH in the samples (expressed in µg/g of wet tissue), absorbances at 412 nm were measured 
on a spectrophotometer. A standard GSH absorbance measurement was also performed. All 
absorbances were measured within 15 minutes of preparation of the samples (Ellman et al., 
1961). On the other hand, for GABA measurement, the brain homogenate was mixed with 
16 mL of ice-cold absolute alcohol inside a bottle, which was then centrifuged for 10 minutes 
at 10000 g. The resultant precipitate was collected and washed 3 times with 10 mL of 90 % 
alcohol. The washed liquids were pooled along with the supernatant. This mixture was evapo-
rated to dryness on a Petri plate at 70 °C. After this, 2 mL water and 4 mL of chloroform were 
added to the dry substance, which was centrifuged at 182 g. The supernatant containing GABA 
was then collected. This was then loaded on a Whatman paper (No. 41) and was subjected to 
chromatography. The mobile phase constituted of n-butanol: acetic acid: water in the ratio of 
50 mL:12 mL:60 mL. Paper chromatography was performed using the ascending technique. 
The spraying agent used was 5 % ninhydrin solution in 95 % ethanol. The chromatograms were 
then dried for 1 h at 90 °C. The blue color spot which developed was cut and heated with 2 mL 
ninhydrin solution on a water bath for 5 min. A small quantity of water (10.0 mL) was added 
to the solution which was kept for 1 h. Eventually, 4 mL of the supernatant was decanted for 
which the absorbance was measured at 570 nm (Tamboli et al., 2012). 
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Picrotoxin (7.5 mg/kg, i.p.) resulted in tonic convulsions followed by 100 % mortality. 
Treatment with clonazepam (1 mg/kg) and liraglutide (100 and 200 mg/kg, i.p.) per se signifi-
cantly delayed onset of convulsions (p < 0.05, p < 0.01 and p < 0.001, respectively). The test 
doses also significantly reduced (p < 0.05 and p < 0.001, respectively) the duration of tonic 
convulsions and reduced mortality in mice as compared to picrotoxin-treated control mice. Ad-
ministration of clonazepam (1 mg/kg) and liraglutide (100 and 200 mg/kg, i.p.) per se signifi-
cantly increased GABA levels (p < 0.01 and p < 0.001, respectively) and GSH levels (p < 0.01 
and p < 0.001 respectively) compared to picrotoxin-treated control (Table 1). It was concluded 
that liraglutide showed significant antiepileptic activity in mice probably through an increase 
in brain GABA and GSH levels. Further studies are necessary to research the details and the 
mechanism of action of this drug so that this drug could be used effectively in the management 
of epilepsy in human beings.  
 
Table 1: Effect of liraglutide and clonazepam on picrotoxin-induced convulsions, the level of Brain GABA 






























100+7.5 659.3±10.43* 57.1±3.43* 3/6 
(50) 
62.1± 0.92** 149.29±7.11** 
Liraglutide + 
Picrotoxin 
200+7.5 703.4±11.81** 32.3±2.94*** 5/6 
(83) 
71.3±0.52*** 179.10±8.40*** 
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